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Abstract 
Purpose: To examine the responsiveness of Functional Assessment of Cancer Therapy-
Prostate (FACT-P) and Short Form-12 Health Survey version 2 (SF-12 v2) in prostate cancer 
patients because there is a lack of evidence to support their responsiveness in prostate cancer 
patients. 
Methods: One hundred sixty-eight subjects with prostate cancer were surveyed at baseline 
and at 6 months using the SF-12 v2 and FACT-P version 4.  Internal responsiveness was 
assessed using paired t-test and generalized estimating equation. External responsiveness was 
evaluated using receiver operating characteristic curve analysis. 
Results:  The internal responsiveness of the FACT-P and SF-12 v2 to detect positive change 
was satisfactory. The FACT-P and SF-12 v2 could not detect negative change.  The FACT-P 
and the SF-12 v2 performed the best in distinguishing between improved general health and 
worsened general health. The FACT-P performed better in distinguishing between unchanged 
general health and worsened general health. The SF-12 v2 performed better in distinguishing 
between unchanged general health and improved general health. 
Conclusions: Positive change detected by these measures should be interpreted with caution 
as they might be too responsive to detect “noise”, which is not clinically significant. The 
ability of the FACT-P and the SF-12 v2 to detect negative change was disappointing. The 
internal and external responsiveness of the Social Well-Being of the FACT-P cannot be 
supported, suggesting that it is not suitable to longitudinally monitor the social component of 
HRQOL in prostate cancer patients. The study suggested that generic and disease–specific 
measures should be used together to complement each other. 
Words Count: 250 out of 250 
  
Running Title: Responsiveness of HRQOL measures for Prostate 
Responsiveness of HRQOL measures for Prostate Cancer Page 4 of 29 
Manuscript Text 
1. Introduction 
According to the worldwide burden of cancer study in 2008, prostate cancer is the second 
most common cancer (in terms of incidence) in adult males worldwide [1]. The reported 
incidence rates of prostate cancer were higher in western countries than other countries most 
likely because of the widespread use of prostate specific antigen (PSA) testing and biopsy in 
these developed countries [1]. The incidence rates of prostate cancer has been rising in most 
Asian countries, thought to be due to westernization of the lifestyle [2]. Through early 
diagnosis by PSA testing and advanced treatment modalities, patients with localized prostate 
cancer nowadays can achieve survival rates close to 100 % [3]. With increased detection of 
prostate cancer and associated advancements in medical technology, changes in the 
epidemiology of the disease are being observed with more diagnoses occurring in younger 
males and at earlier stages of the disease. Prostate cancer patients now live longer with their 
disease. As the health-related quality of life (HRQOL) of patients with prostate cancer are 
often affected either as a direct result of the cancer itself or from side effects of interventions 
[4-8], HRQOL is one of the important clinical outcomes in patients with prostate cancer [9]. 
Many clinical trials include HRQOL as one of the outcome measures in order to fully 
evaluate the effectiveness of prostate cancer treatments [9] and there is significant interest 
amongst oncologists and epidemiologists to explore the trajectories of HRQOL in cancer 
patient populations in order to understand the factors which may influence the change in 
HRQOL over time.  
Many different HRQOL measures are available for prostate cancer patients [9-11]. A recent 
systematic review evaluated the twenty most commonly used HRQOL measures for studies 
on prostate cancer [10]. Among different generic HRQOL measures, the review only 
recommended the Short Form-12 (SF-12) because of its well established psychometric 
properties [10]. Besides, the SF-12 is widely used in general populations and different patient 
populations, worldwide.  The review by Haemoen also recommended the Functional 
Assessment of Cancer Therapy-Prostate (FACT-P) for the specific evaluation of prostate 
cancer patients’ HRQOL because the measure has good psychometric properties [10]. The 
FACT-P consists of prostate cancer subscale and the core module of the Functional 
Assessment of Chronic Illness Therapy (FACIT), which is applicable to all cancer patient 
populations.  
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HRQOL measures should have well-established psychometric properties before application 
in clinical settings and research studies [12]. Responsiveness is one of the most important 
psychometric properties for studies monitoring cohorts over time because responsiveness will 
impact the interpretation of findings and subsequently the conclusions in longitudinal studies 
[13]. The use of a HRQOL measure  that is not responsive can lead to type II error (false 
negative) in clinical trials [14] and inaccurate estimation of HRQOL trajectories in 
longitudinal observational studies. Therefore, the responsiveness of HRQOL measures should 
be confirmed before they are applied in longitudinal studies.  However, there is still a lack of 
evidence on the responsiveness of the SF-12 v2 and FACT-P in patients with prostate cancer.   
Two distinct methods can be used to assess the responsiveness of an instrument: internal 
responsiveness (distribution-based) and external responsiveness (anchor-based). Internal 
responsiveness is the ability of an instrument to detect a clinically important change over time 
induced by an intervention that has been shown to be effective. According to Husted et al, 
paired t-test with effect size statistics was commonly used to evaluate the internal 
responsiveness.  External responsiveness refers to the ability of an instrument to detect a 
clinically important change over time with reference to an external standard for health status 
(external anchor) shown by receiver operating characteristic (ROC) curves [13, 15-17].  
The aims of this study were to examine the internal and external responsiveness of the 
FACT-P and SF-12 v2 measures in Chinese patients with prostate cancer.   
2. Methods 
2.1 Subject and Study Design 
This was a prospective longitudinal study. Convenience sampling of Chinese patients with 
confirmed diagnosis of prostate cancer were recruited in a urological specialist outpatient 
clinic of a teaching hospital in Hong Kong between May 2013 and January 2014. Patients 
were excluded if they (i) refused to give consent, (ii) had hearing problems, (iii) were  not 
able to communicate in Chinese/Cantonese, or (vi) being too ill to complete the questionnaire. 
Subjects who consented were asked to provide their contact details and were subsequently 
interviewed by a trained interviewer who administered the study questionnaire by a face-to-
face interview (baseline). Subjects were contacted again at 6-month after their baseline 
interview to complete a follow-up telephone interview. The interviewer was required to read 
the study questionnaire verbatim in a standardized interview approach. We deliberately used 
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interviewer-administered method because many of our subjects were the elderly with poor 
literacy level. They were not able to complete the questionnaire themselves. Interviewer 
administration can enhance response rates and reduce missing values [18]. 
 2.2 Study instruments 
The Chinese (Hong Kong) Short Form-12 version 2 (SF-12v2) 
The SF-12v2 Health Survey is a generic HRQOL measure with eight subscales (Physical 
functioning, PF; Role physical, RP; Bodily pain, BP; General health, GH; Vitality, VT; 
Social functioning, SF; Role emotional, RE; Mental health, MH) and two summary scales 
(Physical composite summary, PCS-12; Mental composite summary, MCS-12). The possible 
range of each domain score is 0-100. The two summary scores are norm-based scoring with 
the population mean of 50 and standard deviation of 10. A high score indicates better 
HRQOL [19, 20]. This generic instrument is shown to be valid and reliable in Chinese 
population [21]. 
The Functional Assessment of Cancer Therapy-Prostate version 4 (FACT-P version 4) 
FACT-P (version 4) is an extension of the FACT-G HRQOL instrument that emphasizes on a 
range of important aspects of HRQOL specific to patients with prostate cancer. It has 39 
items that are categorized into four FACT-G subscales (Physical well-being, PWB; Social 
well-being, SWB; Emotional well-being, EWB; Functional well-being FWB) and one 
Prostate Cancer Subscale (PCS) addressing the additional concerns about prostate cancer [22]. 
The raw scores are computed to give standard scores in the possible range of 0-28 for the 
PWB, EWB and FWB subscales, 0-24 for the SWB subscale, and 0-48 for the PCS.  A Trial 
Outcome Index (TOI) is the total of PWB, FWB and PCS whereas FACT-P total score is the 
sum of all five subscales with a range of 0-104 for TOI score, 0-108 for FACT-G Total score, 
and 0-156 for FACT-P Total score. Higher scores in subscales and total score indicate better 
HRQOL. The FACT-P (version 4) is a valid, reliable and sensitive  measure to assess the 
HRQOL of Chinese patients with prostate cancer [23].  
Global Rating of Change Scale (GRS) 
The GRS was used as an external anchor because a review paper reported that the GRS was 
typically used in studies which evaluated the responsiveness of instruments [24]. Furthermore, 
the GRS had good face validity, construct validity, test-retest reliability [24]. A previous 
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study which evaluated the internal and external responsiveness of Functional Assessment of 
Cancer Therapy-Colorectal and the SF-12 v2 also used the GRS as an external anchor [25]. 
All subjects were asked this single item scale during their 6-month follow-up interview to 
evaluate their subjective changes in global health condition by a retrospective question 
“Compared to the first visit (six months ago), how would you rate your overall health now?” 
[26]. The response was rated on a 7-point ordinal scale ranging from -3 to 3 anchored from 
the much worse to the much better options, with 0 indicating no change.  The GRS has been 
commonly used as the external criterion to estimate minimal clinically important difference 
and responsiveness of measures [25, 27-33]. 
2.3 Statistical Analysis 
Responsiveness was assessed using the self-reported health change anchor to define samples 
reflecting “unchanged” (rating of 0), “improved” (rating of 1 to 3) and “worsened” (rating of 
-3 to -1) in health status [15]. Mean and standard deviation of all HRQOL scores were 
calculated for each sample. 
Internal responsiveness 
For assessing the internal responsiveness, mean changes over the past six months were tested 
by paired t-test in patients who were classified as “worsened”, “unchanged” and “Improved”. 
The HRQOL score differences between baseline and follow-up assessments were also tested 
using the  standardized effect size (SES) [26], standardized response mean (SRM) [34] and 
responsiveness statistics (RS) [29, 35, 36] separately for each groups. Three responsiveness 
statistics were reported because the method for calculating the most appropriate 
responsiveness statistic was still controversial [17]. Appendix 1 shows the equations of these 
three responsiveness statistics 
The value of SES, SRM and RS were interpreted as trivial for <0.2, small for ≥0.2 and <0.5, 
moderate for ≥0.5 and <0.8 or large for ≥0.8, according to criteria defined by Cohen [37], 
Liang [34] and Norman [38] respectively. Internal responsiveness was supported if these 
changes were interpreted as small or above. Thus, 95% bootstrap bias-corrected and 
accelerated confidence intervals [39] for SES, SRM and RS were obtained using the 
bootstrapping estimation method with 2000 replications.  
Sensitivity analysis was conducted using generalized estimating equation (GEE) model by 
Global Rating on Change Scale after multiple imputation, controlling for baseline socio-
Running Title: Responsiveness of HRQOL measures for Prostate 
Responsiveness of HRQOL measures for Prostate Cancer Page 8 of 29 
demographic and clinical characteristics. Multiple imputation was used to handle the missing 
date. In this sensitivity analysis, each missing value was imputed by the chained equation 
method 20 times. For each of the 20 imputed datasets, the same analysis was performed with 
the twenty sets of results combined using Rubin’s combination rules [40]. To confirm the 
internal responsiveness of the instruments over times accounting for within-subject 
correlation with repeated measurements, GEE assigning time as dependent variables with an 
identity link function was conducted. 
External responsiveness  
Based on the recommendation by Husted et al [17] and Deyo et al[41], we evaluated the 
external responsiveness of these measures by receiver operating characteristic (ROC) curve 
analysis. However, it should be noted that one of the major disadvantages of the ROC method 
is that the external anchor must be dichotomized. Therefore, we had three different 
comparisons: (i) improved vs. unchanged group, (ii) improved vs. worsened group, and (iii) 
worsened vs. unchanged group.   First, independent t-tests were performed to compare the 
mean changes between groups. Subsequently, the ROC curve analysis was performed to 
assess the ability of these measures to detect HRQOL score change with health condition 
changes or to discriminate between groups. The ROC curve is a plot of the true-positive rate 
(sensitivity) against the false-positive rate (1-specificity). Conceptually, the ROC curve can 
provide an overview of the relationship between a measure and an external anchor. The area 
under a ROC curve (AUC) can show the probability that a measure correctly classified 
patients according to the external anchor. Perfect discriminatory power is defined as a value 
of 1 but a value of 0.5 is considered no discriminatory power. To support the external 
responsiveness, the AUC was considered adequate for ≥ 0.7 [17, 42] and its 95% confidence 
intervals were reported. 
All statistical analyses were conducted by the Stata 13 (StataCorp, College Station, TX) with 
p-values < 0.05 indicating statistical significance. 
3. Results 
3.1 Baseline Characteristics  
A total of 339 patients with prostate cancer were invited to join the study. Of the 339 patients, 
29 patients refused to participate. A further 19 patients were excluded because of hearing 
problems, inability to communicate in Chinese/Cantonese, or being too ill to complete the 
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questionnaire. Among them, 291 eligible subjects (response rate: 85.9 %) completed baseline 
interviews. Of the 291 subjects, 168 subjects completed 6-month follow-up interviews 
(attrition rate: 42.3%). Subject recruitment flowchart is shown in figure 1. Baseline 
characteristics of defaulted and followed subjects are shown in table 1. The age of our 
subjects at baseline ranged from 41 to 99 years old. There were statistically significant 
differences in mean age, educational attainment, marital status, Karnofsky performance status, 
treatment (radical prostatectomy), all FACT-P scores (except EWB) and all SF-12 v2 scores 
(except MCS-12) between subjects who completed 6-month telephone follow-up interviews 
and those who did not.  
Baseline and 6-month follow-up on the HRQOL scores are shown in Table 2. In both 
baseline and 6-month follow-up interviews, the means of the FACT-G and FACT-P total 
score were greater than 80% of the maximum possible score for each scale, respectively. The 
mean change of the PWB, EWB, TOI and Prostate Cancer Subscale, FACT-G total scale and 
FACT-P was statistically significant between the two time points (P-value < 0.001). In regard 
to the SF-12 v2, the baseline PCS-12 score was lower than 50 (the population mean) whilst 
the bassline MCS-12 score was higher than 50. The mean change of the RP, BP, VT, RE and 
MH and MCS-12 was statistically significant between the two time points (P-value< 0.001).  
Table 3 shows that most subjects reported no change (71.43%) in the GRS. 8.34% and 
20.24% of subjects rate “deterioration”  and “improvement” in current general health 
conditions, compared to six months ago, respectively.  
3.2 Internal Responsiveness  
A summary of the mean change and responsiveness statistics for each group (i.e. worsened, 
unchanged and improved) is shown in Table 4. The results of sensitivity analysis are shown 
in table 5. 
3.2.1 The FACT-P 
In the worsened group, the score of the FACT-G and FACT-P total scales, FWB, PCS, and 
TOI decreased statistically significantly (deterioration in HRQOL), with all responsiveness 
statistics >0.2. In the improved group, all total and subscale scores, except for the SWB score, 
increased statistically significantly (improvement in HRQOL), with all responsiveness 
statistics >0.2. In the unchanged group, all total and subscale scores, except for the SWB and 
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FWB scores also increased statistically significantly but all responsiveness statistics in the 
unchanged group were smaller than those in the improved group.   
The sensitivity analysis showed that all scores, except for the SWB score, increased 
statistically significantly in both improved group and unchanged group but all of the 
coefficients in the unchanged group, except for the PWB subscale, were smaller than those in 
the improved group. In contrast, all scales of the FACT-P did not detect any statistically 
significant difference in the worsened group.  
3.2.2 The SF-12 v2  
In the worsened group, the score of the PF, GH and SF domain and the PCS-12 decreased 
statistically significantly (deterioration in HRQOL), with all responsiveness statistics >0.2. In 
the improved group, all domain and summary scores of the SF-12 v2 increased statistically 
significantly improvement in HRQOL), with all responsiveness statistics >0.2. In the 
unchanged group, the score of the BP, VT, MH domains and MCS-12 also increased 
statistically significantly but all responsiveness statistics in the unchanged group were smaller 
than those in the improved group. 
The sensitivity analysis showed that all SF-12 v2 domain scores and summary scores 
increased statistically significantly in the improved group. In the unchanged group, all 
summary and domain scores, except for the GH and SF domain scores also increased 
statistically significantly but all of the coefficients in the unchanged group, except for the RE 
domain, were smaller than those in the improved group. In contrast, all domains, PCS-12 and 
MCS-12 did not detect any statistically significant difference in the worsened group.  
3.3 External responsiveness 
Table 6 shows the difference in mean change and the AUC of ROC (i) between improved and 
unchanged group, (ii) between improved and worsened group, and (iii) between worsened 
and unchanged group.    
Only the RP and PCS-12 of the SF-12 v2 could detect the difference in mean change between 
improved and unchanged group with the AUC standard of at least 0.70. The AUC of ROC 
was just short of 0.7 in the PWB (0.68), the TOI (0.69) and the FACT-P total scale (0.69). 
The FACT-P and SF-12 v2 (except the SWB of the FACT-P, and the BP, RE and MCS-12 of 
the SF-12 v2) could detect the difference in mean change between improved and worsened 
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group with the AUC standard of at least 0.70.  The FACT-P (except the SWB and EWB) and 
only the PF of the SF-12 v2 could detect the difference in mean change between worsened 
and unchanged group with the AUC standard of at least 0.70.   
Figure 2 shows the AUC of ROC of the PCS-12 and MCS-12 of the SF-12 v2, FACT-G and 
FACT-P total scales.  
4. Discussion 
To the best of our knowledge, this was the first study to focus on the assessment of the 
internal and external responsiveness of the SF-12 v2 and the FACT-P, which were 
recommended to evaluate the HRQOL of prostate cancer patients. It should be emphasized 
that it was not the aim of this study to compare the responsiveness of these two HRQOL 
measures. These measures are designed for completely different purposes. Furthermore, 
although the names of domains are similar (physical well-being in the FACT-P vs. physical 
functioning in the SF-12 v2), their respective contents are different substantially. A strong 
evidence for this was provided in table 2 where the PWB showed an increase but the PF a 
decrease over time.  Therefore, a direct comparison is meaningless. Instead, these measures 
should be used complementarily.  
Assessment of internal responsiveness by paired t-test and GEE confirmed that all scales of 
the FACT- P (except SWB subscale) and all domains and component summaries of the SF-12 
v2 were responsive to positive change in subjects with improved general health. The SES and 
SRM in the improved group were the highest in the PWB subscale of the FACT-P, indicating 
that it was the most internally responsive to capture positive HRQOL changes in patients with 
prostate cancer, compared with SWB, EWB and FWB. However, the improvement detected 
by the PWB subscale should be interpreted with caution because in the sensitivity analysis, it 
was found that the unchanged group had a larger improvement in the PWB score than the 
improved group.  
The sensitivity analysis suggested that the ability of the FACT-P and the SF-12 v2 to detect 
negative change in subjects with worsened general health was disappointing. The FACT-P 
and the SF-12 v2 were not responsive to negative change, overall. Our findings were contrary 
to the findings of another study which found that the PWB subscale was the most responsive 
to capture negative HRQOL change in Chinese patients with colorectal cancer [25]. There 
were some possible explanations. First, patients with worsened general health did not 
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necessarily have deteriorations in cancer-specific HRQOL. Second, compared with other 
cancer types, prostate cancer is relatively “indolent” with a slow progressive course and 
consequently, prostate cancer may have a less aggressive impact on patients’ generic and 
cancer-specific HRQOL.  
Noteworthy, the change detected by the FACT-P and SF-12 v2 should be interpreted with 
caution because positive changes were also detected in stable groups in some subscales/ 
domains even though the responsiveness statistics / coefficients in the stable group were 
smaller than those in the improved group.  The measures might be too responsive. As a 
consequence, the positive changed detected in the stable group might be due to “noises”, 
which are not clinically meaningful [25].  
Compared with other subscales of the FACT-P, the internal responsiveness of the SWB was 
disappointing because it did not detect any change in neither improved group nor worsened 
group. One the contrary, a previous study in Chinese patients with colorectal cancer found 
that the SWB scale could detect positive change in “improved”, “unchanged” and “worsened” 
group [25]. There were some possible explanations. First, the poorer internal responsiveness 
of the SWB subscale might be related to poor reproducibility [43] and the weak convergent 
validity of the SWB scale [23, 44].  Second, the question items such as “I feel close to my 
friends” and “I get support from my friends” might not be necessarily relevant in Chinese 
culture in which friends are not the primary support and recourse. Further studies are needed 
to evaluate and compare the content validity and relevance of the core module of the FACT 
in different cancer populations.  
Concerning the external responsiveness, the FACT-P and the SF-12 v2 performed the best in 
distinguishing between subjects who had improved general health and those with worsened 
general health. Compared with the SF-12 v2, the FACT-P performed better in distinguishing 
between subjects who had unchanged general health and those with worsened general health. 
On the contrary, the SF-12 v2 performed slightly better in distinguishing between subjects 
who had unchanged general health and those with improved general health. Nevertheless, 
some of the AUC in the FACT-P were marginally acceptable, with the AUC just short of 0.7. 
Similar to the findings of internal responsiveness, the SWB had poor external responsiveness, 
with the AUC< 0.6 in three comparisons. The external responsiveness of the SWB was also 
problematic in Chinese patients with colorectal cancer [25].  
5. Limitation 
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There were some limitations in the present study. First, the GRS might also be too generic. 
Thus, people with improved health status as measured by the GRS did not necessarily have 
improvement in disease-specific HRQOL, and vice versa [33]. However, the GRS was still 
the most commonly used external anchor to evaluate the responsiveness of instruments 
because of its validity and reliability. Besides, further study might use other cancer-specific 
HRQOL instruments as an external anchor. However, those questionnaires were lengthier, 
which might increase the burden of respondents. Second, the baseline data were collected by 
face-to-face interviews whilst the follow-up data were collected by telephone interviews. The 
difference in the administration mode between two interviews might lead to differences in 
scores. However, it was not feasible to request our study subjects to go to the hospital to 
finish the 6-month follow-up interview.  In order to minimize the potential effects caused by 
the change in administration mode, the same interviewer conducted all the baseline and 
follow-up interviews. Furthermore, the interviewer was required to read the questionnaire 
verbatim in a standardized approach. Third, it was a convenience sample which might 
threaten the external validity of our study findings. Further study might use consecutive 
sampling methods to recruit study subjects.  Finally, patients who were too ill to consent were 
excluded, which might lead to the low sample numbers in the “worsened group”.  
6. Conclusion 
Assessment of internal responsiveness by paired t-test and GEE confirmed that all scales of 
the FACT- P (except SWB subscale) and all domains and component summaries of the SF-12 
v2 were responsive to positive change in subjects with improved general health. On the 
contrary, the results of the GEE suggested that the FACT-P and the SF-12 v2 were not 
responsive to negative change. Besides, positive change detected by these measures should be 
interpreted with caution as they might be too responsive to detect “noise”, which is not 
clinically significant.  Concerning the external responsiveness, the FACT-P and the SF-12 v2 
performed the best in distinguishing between improved l health and worsened health. The 
FACT-P performed better in distinguishing between unchanged health and worsened health. 
The SF-12 v2 performed better in distinguishing between unchanged health and improved 
health. These findings suggested that both generic and disease–specific measures should be 
used together to complement each other. 
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Table 1. Baseline Characteristics of Prostate Cancer Patients     





 N %  N %  N % 
Demographic Characteristics      
Age, Mean (SD)** 74.9 (8.6)  72.9(8.0)  77.7 (8.7) 
Education ##         
 No formal schooling 46 15.8%  16 9.5%  30 24.4% 
 Primary 98 33.7%  58 34.5%  40 32.5% 
 Secondary 90 30.9%  64 38.1%  26 21.1% 
 Tertiary or above 53 18.2%  28 16.7%  25 20.3% 
 Unknown 4 1.4%  2 1.2%  2 1.6% 
Marital Status#         
 Married 222 76.3%  138 82.1%  84 68.3% 
 Single 17 5.8%  10 6.0%  7 5.7% 
 Separated, divorced or widower 48 16.5%  18 10.7%  30 24.4% 
 Unknown 4 1.4%  2 1.2%  2 1.6% 
Currently Working         
 Yes 25 8.6%  20 11.9%  5 4.1% 
 No 262 90.0%  146 86.9%  116 94.3% 
 Unknown 4 1.4%  2 1.2%  2 1.6% 
Monthly income (HKD$)         
 ≤20,000 238 81.8%  133 79.2%  105 85.4% 
 >20,000 49 16.8%  33 19.6%  16 13.0% 
 Unknown 4 1.4%  2 1.2%  2 1.6% 
Clinical Characteristics         
PSA         
 <0.1ng/ml 109 37.5%  70 41.7%  39 31.7% 
 ≥0.1 & <10ng/ml 121 41.6%  60 35.7%  61 49.6% 
 ≥10ng/ml 39 13.4%  24 14.3%  15 12.2% 
 Unknown 22 7.6%  14 8.3%  8 6.5% 
AJCC Cancer Stage         
 I 58 19.9%  27 16.1%  31 25.2% 
 II 75 25.8%  42 25.0%  33 26.8% 
 III 31 10.7%  20 11.9%  11 8.9% 
 IV 112 38.5%  70 41.7%  42 34.1% 
 Unknown 15 5.2%  9 5.4%  6 4.9% 
Distant metastasis 59 20.3%  37 22.0%  22 17.9% 
KPS ##         
 Mean (SD)** 91.4 (12.5)  94.1 (8.7)  87.6  (15.6) 
 ≤70 23 7.9%  5 2.98%  18 14.6% 
 80 34 11.7%  16 9.52%  18 14.6% 
 90 64 22.0%  39 23.21%  25 20.3% 
 100 138 47.4%  90 53.57%  48 39.0% 
 Unknown 32 11.0%  18 10.71%  14 11.4% 
Treatments         
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Watchful waiting/ active 
surveillance 24 8.2%  12 7.1%  12 9.8% 
 
Androgen deprivation/ 
Combined androgen blockade 117 40.2%  65 38.7%  52 42.3% 
 Radical prostatectomy# 102 35.1%  68 40.5%  34 27.6% 
 Radical curative radiation 45 15.5%  26 15.5%  19 15.4% 
 Adjuvant radiation 8 2.7%  4 2.4%  4 3.3% 
 Chemotherapy 4 1.4%  2 1.2%  2 1.6% 
HRQOL scores Mean (SD)  Mean (SD)  Mean (SD) 
Condition-specific, FACT-P      
PWB** 24.6 (3.6)  25.7 (2.6)  23.2 (4.3) 
SWB** 19.6 (5.2)  20.6 (4.3)  18.3 (6.0) 
EWB 21.1  (3.8)  21.4 (3.3)  20.7 (4.3) 
FWB** 19.7  (5.4)  20.9 (4.7)  18.1 (5.8) 
PCS** 35.9 ± (6.5)  37.5 (5.6)  33.7 (6.9) 
TOI** 80.2 ± (13.7)  84.0 (11.3)  75.0 (15.0) 
FACT-G Total score** 85.0 ± (13.9)  88.5 (11.6)  80.3 (15.4) 
FACT-P Total score** 120.9 ± (19.2)  126.0 (16.0)  114.0 (21.1) 
Generic, SF-12v2         
PF** 67.2 (34.7)  78.7 (28.4)  51.2 (36.3) 
RP** 71.1 (26.9)  78.9 (22.8)  60.5 (28.4) 
BP** 75.1 (27.6)  82.6 (22.2)  64.7 (30.9) 
GH** 59.4 (27.2)  67.1 (24.1)  48.8 (27.9) 
VT** 70.1 (24.6)  75.1 (23.3)  63.1 (24.7) 
SF** 76.7 (26.2)  82.9 (22.6)  68.2 (28.4) 
RE* 84.8 (22.2)  87.6 (19.4)  80.9 (25.2) 
MH** 81.3 (19.3)  84.4 (17.3)  76.8 (21.0) 
PCS-12** 43.4 (13.5)  47.8 (10.7)  37.3 (14.6) 
MCS-12 57.4 (9.9)  58.0 (8.9)  56.5 (11.2) 
Note:         
SD=standard deviation; PSA=Prostate-specific antigen; KPS=Karnofsky performance status; 
AJCC=American Joint Committee on Cancer ; HRQOL=health-related quality of life;  FACT-P subscales: 
PWB=physical well-being; SWB=social well-being; EWB=emotional well-being; FWB=functional well-
being; PCS=prostate cancer subscale; TOI=trial outcome index; SF-12v2 subscales: PF=physical 
functioning; RP=role physical; BP=bodily pain; GH=general health; VT=vitality; SF=social functioning; 
RE=role emotional; MH=mental health; PCS-12=physical component summary 12; MCS-12=mental 
component summary 12; 
* : p-value <0.05 by independent t-test         
** : p-value <0.01 by independent t-test         
# : p-value <0.05 by chi-square test         
## : p-value <0.01 by chi-square test         
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 Table 2. Baseline,  6-month Follow-up and Mean Change on the Condition-specific and Generic HRQOL 
scores of Patients (n=168) 




PWB (range 0-28) 25.68 (2.61) 26.66 (2.60) 0.98 (2.26) < 0.001* 
SWB (range 0-24) 20.56 (4.29) 20.75 (4.71) 0.19 (3.41) 0.464 
EWB (range 0-28) 21.38 (3.31) 22.40 (2.89) 1.03 (2.30) < 0.001* 
FWB (range 0-28) 20.87 (4.71) 21.20 (5.03) 0.33 (3.56) 0.235 
PCS (range 0-48) 37.49 (5.63) 39.17 (5.04) 1.68 (4.52) < 0.001* 
TOI (range 0-104) 84.04 (11.33) 87.02 (11.59) 2.99 (8.60) < 0.001* 
FACT-G Total score 
(range 0-108) 88.49 (11.57) 91.02 (12.34) 2.53 (7.41) < 0.001* 
FACT-P Total score  
 (range 0-156) 125.98 (16.01) 130.18 (16.70) 4.21 (10.84) < 0.001* 
Generic, SF-12v2 
   
 
PF (range 0-100) 78.72 (28.38) 77.83 (29.65) -0.89 (25.06) 0.645 
RP (range 0-100) 78.87 (22.85) 84.00 (21.41) 5.13 (22.37) 0.003* 
BP (range 0-100) 82.59 (22.19) 90.48 (17.90) 7.89 (20.50) < 0.001* 
GH (range 0-100) 67.11 (24.06) 65.15 (23.57) -1.96 (20.03) 0.205 
VT (range 0-100) 75.15 (23.29) 88.39 (19.32) 13.24 (21.87) < 0.001* 
SF (range 0-100) 82.89 (22.58) 82.89 (19.56) 0.00 (19.54) 1.000 
RE (range 0-100) 87.65 (19.39) 91.00 (18.20) 3.35 (17.06) 0.012* 
MH (range 0-100) 84.45 (17.28) 90.25 (16.33) 5.80 (16.69) < 0.001* 
PCS-12 mean :50(SD:10) # 47.83 (10.67) 48.44 (9.86) 0.61 (8.58) 0.355 
MCS-12 mean :50(SD:10)# 57.99 (8.85) 60.91 (8.54) 2.92 (7.43) < 0.001* 
Note: 
   
 
HRQOL=health-related quality of life; SD=standard deviation; FACT-P subscales: PWB=physical well-being; 
SWB=social well-being; EWB=emotional well-being; FWB=functional well-being; PCS=prostate cancer 
subscale; TOI=trial outcome index; SF-12v2 subscales: PF=physical functioning; RP=role physical; BP=bodily 
pain; GH=general health; VT=vitality; SF=social functioning; RE=role emotional; MH=mental health; PCS-
12=physical component summary 12; MCS-12=mental component summary 12 
* Significant Difference on HRQOL between Baseline and 6-month follow-up  
† Higher scores represents a higher level of functioning or a better HRQOL.  
# mean 50 with SD :10 due to norm-based scoring  
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Table 3. Distribution of Global Rating on Change Scale 
     
Response Follow-up (n=168) 
  -2 worse 3 (1.79%) 
  -1 a little worse 11 (6.55%) 
  0 same 120 (71.43%) 
  1 a little better 31 (18.45%) 
  2 better 3 (1.79%) 
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Table 4. Mean Change, Standardized Effect Size, Standardized Response Mean and Responsiveness Statistic of HRQOL Scores by Global Rating on Change Scale (n=168) 
Measure/Subscale† 
Mean (SD) at 
baseline 
Mean (SD) at 6-
month follow-up Mean Change (SD) P-value SES (95% CI) SRM (95% CI) RS  (95% CI) 
Worsened group (n=14)               
Condition-specific, FACT-P       
 
PWB 24.00 (3.21) 22.21 (5.48) -1.79 (4.63) 0.172 -0.33 (-0.70,0.10) -0.39 (-0.79,0.19) -1.09 (-3.23,0.08) 
SWB 19.77 (5.56) 19.00 (5.14) -0.77 (4.06) 0.489 -0.15 (-0.80,0.27) -0.19 (-0.70,0.46) -0.22 (-0.91,0.33) 
EWB 19.71 (5.08) 19.07 (5.95) -0.64 (3.97) 0.555 -0.11 (-0.56,0.12) -0.16 (-0.67,0.56) -0.34 (-2.62,0.34) 
FWB 19.21 (4.37) 14.86 (5.83) -4.36 (4.07) 0.001* -0.75 (-1.18,-0.40) -1.07 (-1.68,-0.55) -1.34 (-2.11,-0.69) 
PCS 35.57 (4.50) 31.64 (7.97) -3.93 (6.59) 0.044* -0.49 (-0.77,-0.20) -0.60 (-0.89,-0.24) -1.30 (-3.16,-0.43) 
TOI 78.79 (10.07) 68.71 (18.32) -10.07 (13.66) 0.016* -0.55 (-0.80,-0.33) -0.74 (-0.99,-0.45) -1.70 (-3.66,-0.79) 
FACT-G Total score 82.70 (13.35) 75.14 (18.00) -7.56 (11.07) 0.024* -0.42 (-0.73,-0.10) -0.68 (-1.05,-0.03) -1.27 (-2.49,-0.43) 
FACT-P Total score 118.27 (16.46) 106.79 (24.92) -11.49 (16.79) 0.024* -0.46 (-0.77,-0.17) -0.68 (-0.95,-0.15) -1.50 (-3.15,-0.56) 
Generic, SF-12v2    
    
PF 67.86 (37.25) 42.86 (33.15) -25.00 (40.43) 0.038* -0.75 (-1.59,0.08) -0.62 (-1.37,0.19) -1.22 (-2.20,0.00) 
RP 67.86 (27.17) 58.93 (18.62) -8.93 (25.68) 0.216 -0.48 (-1.14,0.18) -0.35 (-0.84,0.24) -0.44 (-1.35,0.14) 
BP 75.00 (27.74) 73.21 (24.93) -1.79 (31.72) 0.836 -0.07 (-0.68,0.71) -0.06 (-0.60,0.57) -0.10 (-1.20,0.74) 
GH 49.64 (27.14) 29.64 (26.99) -20.00 (29.61) 0.025* -0.74 (-1.57,-0.12) -0.68 (-1.15,0.02) -1.17 (-2.27,-0.38) 
VT 69.64 (22.31) 71.43 (27.49) 1.79 (28.53) 0.818 0.06 (-0.65,0.55) 0.06 (-0.56,0.66) 0.09 (-0.93,0.78) 
SF 71.43 (27.49) 57.14 (20.64) -14.29 (18.90) 0.014* -0.69 (-1.13,-0.12) -0.76 (-1.36,0.00) -0.86 (-1.48,-0.21) 
RE 81.25 (25.36) 73.21 (28.53) -8.04 (25.76) 0.264 -0.28 (-0.78,0.11) -0.31 (-0.72,0.27) -0.50 (-1.81,0.18) 
MH 81.25 (20.07) 76.79 (21.29) -4.46 (21.15) 0.444 -0.21 (-0.78,0.32) -0.21 (-0.74,0.39) -0.31 (-1.16,0.48) 
PCS-12 42.49 (14.30) 35.70 (9.18) -6.79 (11.72) 0.049* -0.74 (-1.45,-0.02) -0.58 (-1.08,-0.02) -1.00 (-2.10,-0.27) 
MCS-12 56.16 (11.25) 55.16 (14.03) -1.01 (11.00) 0.737 -0.07 (-0.52,0.34) -0.09 (-0.61,0.53) -0.17 (-1.35,0.67) 
Unchanged group (n=120)     
   
Condition-specific, FACT-P     
   
PWB 25.94 (2.54) 26.94 (1.83) 1.00 (1.64) < 0.001* 0.55 (0.36,0.75) 0.61 (0.40,0.77) 0.61 (0.40,0.77) 
SWB 20.88 (4.25) 21.08 (4.79) 0.20 (3.48) 0.539 0.04 (-0.09,0.16) 0.06 (-0.12,0.23) 0.06 (-0.13,0.24) 
EWB 21.78 (2.91) 22.75 (2.22) 0.97 (1.91) < 0.001* 0.44 (0.25,0.66) 0.51 (0.36,0.63) 0.51 (0.35,0.64) 
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FWB 21.28 (5.00) 21.74 (4.81) 0.46 (3.25) 0.125 0.10 (-0.03,0.23) 0.14 (-0.05,0.30) 0.14 (-0.04,0.31) 
PCS 38.24 (5.27) 39.87 (4.14) 1.63 (3.03) < 0.001* 0.39 (0.26,0.55) 0.54 (0.35,0.72) 0.54 (0.34,0.71) 
TOI 85.47 (11.27) 88.55 (9.70) 3.08 (5.93) < 0.001* 0.32 (0.20,0.44) 0.52 (0.32,0.70) 0.52 (0.32,0.70) 
FACT-G Total score 89.89 (11.53) 92.51 (11.31) 2.62 (5.96) < 0.001* 0.23 (0.14,0.34) 0.44 (0.27,0.62) 0.44 (0.25,0.62) 
FACT-P Total score 128.13 (15.69) 132.38 (14.75) 4.25 (7.64) < 0.001* 0.29 (0.19,0.39) 0.56 (0.37,0.74) 0.56 (0.35,0.75) 
Generic, SF-12v2    
    
PF 81.67 (26.48) 79.38 (28.38) -2.29 (20.50) 0.223 -0.08 (-0.20,0.05) -0.11 (-0.28,0.07) -0.11 (-0.27,0.08) 
RP 81.88 (21.67) 84.06 (21.68) 2.19 (20.22) 0.238 0.10 (-0.08,0.28) 0.11 (-0.08,0.31) 0.11 (-0.09,0.31) 
BP 84.38 (21.27) 91.67 (17.55) 7.29 (18.73) < 0.001* 0.42 (0.20,0.70) 0.39 (0.23,0.52) 0.39 (0.24,0.53) 
GH 69.79 (22.71) 66.88 (21.88) -2.92 (17.12) 0.064 -0.13 (-0.27,0.01) -0.17 (-0.35,0.02) -0.17 (-0.35,0.02) 
VT 77.92 (23.19) 89.79 (18.19) 11.88 (18.89) < 0.001* 0.65 (0.44,0.94) 0.63 (0.48,0.79) 0.63 (0.47,0.77) 
SF 86.25 (20.71) 84.38 (18.64) -1.88 (16.58) 0.218 -0.10 (-0.25,0.05) -0.11 (-0.27,0.06) -0.11 (-0.28,0.08) 
RE 88.13 (18.96) 91.98 (17.13) 3.85 (16.03) 0.010* 0.22 (-0.01,0.44) 0.24 (-0.03,0.44) 0.24 (-0.02,0.43) 
MH 86.35 (16.20) 91.15 (15.99) 4.79 (14.33) < 0.001* 0.30 (0.12,0.53) 0.33 (0.14,0.51) 0.33 (0.16,0.51) 
PCS-12 49.06 (9.77) 48.86 (9.73) -0.20 (6.80) 0.750 -0.02 (-0.14,0.10) -0.03 (-0.22,0.14) -0.03 (-0.19,0.16) 
MCS-12 58.66 (8.60) 61.42 (7.86) 2.75 (6.07) < 0.001* 0.35 (0.19,0.52) 0.45 (0.26,0.62) 0.45 (0.26,0.62) 
Improved group (n=34)    
    
Condition-specific, FACT-P    
    
PWB 25.44 (2.35) 27.50 (0.90) 2.06 (1.82) < 0.001* 2.30 (1.65,3.37) 1.13 (0.83,1.43) 1.26 (0.87,1.75) 
SWB 19.75 (3.83) 20.33 (4.12) 0.58 (2.86) 0.244 0.14 (-0.10,0.35) 0.20 (-0.18,0.52) 0.17 (-0.13,0.44) 
EWB 20.65 (3.52) 22.56 (2.31) 1.91 (2.31) < 0.001* 0.83 (0.25,1.63) 0.83 (0.61,1.10) 1.00 (0.57,1.50) 
FWB 20.09 (3.47) 21.88 (3.52) 1.79 (2.80) < 0.001* 0.51 (0.27,0.82) 0.64 (0.33,0.91) 0.55 (0.27,0.90) 
PCS 35.62 (6.73) 39.80 (3.95) 4.18 (5.79) < 0.001* 1.06 (0.48,2.06) 0.72 (0.43,1.04) 1.38 (0.92,2.41) 
TOI 81.15 (11.10) 89.18 (7.27) 8.03 (8.70) < 0.001* 1.11 (0.68,1.78) 0.92 (0.57,1.41) 1.36 (0.95,2.12) 
FACT-G Total score 85.93 (9.95) 92.27 (8.05) 6.35 (6.58) < 0.001* 0.79 (0.53,1.19) 0.97 (0.54,1.37) 1.06 (0.70,1.51) 
FACT-P Total score 121.54 (15.52) 132.07 (11.33) 10.53 (11.28) < 0.001* 0.93 (0.59,1.49) 0.93 (0.55,1.43) 1.38 (0.96,2.08) 
Generic, SF-12v2    
    
PF 72.79 (29.75) 86.76 (22.39) 13.97 (23.19) 0.001* 0.62 (0.30,1.07) 0.60 (0.32,0.85) 0.68 (0.31,1.16) 
RP 72.79 (23.12) 94.12 (10.76) 21.32 (20.30) < 0.001* 1.98 (1.30,3.01) 1.05 (0.74,1.40) 1.05 (0.62,1.53) 
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BP 79.41 (22.59) 93.38 (11.20) 13.97 (19.65) < 0.001* 1.25 (0.72,2.05) 0.71 (0.43,1.02) 0.75 (0.38,1.18) 
GH 64.85 (24.88) 73.68 (13.33) 8.82 (19.15) 0.011* 0.66 (0.24,1.22) 0.46 (0.17,0.76) 0.52 (0.16,0.94) 
VT 67.65 (22.64) 90.44 (16.30) 22.79 (25.65) < 0.001* 1.40 (0.67,2.37) 0.89 (0.53,1.26) 1.21 (0.72,1.76) 
SF 75.74 (24.22) 88.24 (14.08) 12.50 (23.23) 0.004* 0.89 (0.35,1.58) 0.54 (0.23,0.84) 0.75 (0.31,1.28) 
RE 88.60 (18.30) 94.85 (11.96) 6.25 (14.84) 0.019* 0.52 (0.14,1.25) 0.42 (0.18,0.65) 0.39 (0.09,0.83) 
MH 79.04 (18.90) 92.65 (12.73) 13.60 (19.55) < 0.001* 1.07 (0.46,1.97) 0.70 (0.35,1.00) 0.95 (0.51,1.48) 
PCS-12 45.66 (11.38) 52.19 (5.76) 6.53 (9.51) < 0.001* 1.13 (0.58,1.80) 0.69 (0.42,0.96) 0.96 (0.48,1.53) 
MCS-12 56.36 (8.64) 61.48 (7.30) 5.13 (9.33) 0.003* 0.70 (0.22,1.47) 0.55 (0.22,0.90) 0.84 (0.36,1.42) 
Note:    
    HRQOL=health-related quality of life; SD=standard deviation; FACT-P subscales: PWB=physical well-being; SWB=social well-being; EWB=emotional well-being; FWB=functional well-being; PCS=prostate cancer 
subscale; TOI=trial outcome index; SF-12v2 subscales: PF=physical functioning; RP=role physical; BP=bodily pain; GH=general health; VT=vitality; SF=social functioning; RE=role emotional; MH=mental health; 
PCS-12=physical component summary 12; MCS-12=mental component summary 12; SES=standardized effect size; SRM=standardized response mean; RS=responsiveness statistic 
* Significant Difference on HRQOL between Baseline and 6-month follow-up  
    
† Higher scores represents a higher level of functioning or a better HRQOL.  
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Table 5. Sensitivity analysis of HRQOL Scores using generalized estimating equations by Global Rating on Change Scale after multiple imputation 
Measure/Subscale† 
Worsened group Unchanged group Improved group 
Coefficient (95% CI) P-value Coefficient (95% CI) P-value Coefficient (95% CI) P-value 
Condition-specific, FACT-P 
      
PWB 0.57 (-2.58,3.73) 0.722 1.94 (1.38,2.50) < 0.001* 1.74 (0.91,2.57) < 0.001* 
SWB 0.13 (-1.96,2.22) 0.904 0.83 (-0.06,1.71) 0.067 0.73 (-0.69,2.15) 0.312 
EWB 1.33 (-1.71,4.37) 0.390 1.26 (0.72,1.80) < 0.001* 1.54 (0.69,2.38) < 0.001* 
FWB -2.24 (-5.32,0.85) 0.155 1.33 (0.50,2.17) 0.002* 1.49 (0.47,2.50) 0.004* 
PCS -1.21 (-5.43,3.00) 0.572 2.94 (2.00,3.88) < 0.001* 3.33 (1.36,5.31) 0.001* 
TOI -2.88 (-12.73,6.97) 0.567 6.21 (4.21,8.22) < 0.001* 6.57 (3.36,9.77) < 0.001* 
FACT-G Total score -0.20 (-9.72,9.32) 0.966 5.36 (3.30,7.42) < 0.001* 5.50 (2.72,8.29) < 0.001* 







 PF -13.01 (-35.61,9.58) 0.259 8.30 (3.04,13.56) 0.002* 13.26 (4.13,22.39) 0.004* 
RP 2.54 (-14.45,19.52) 0.770 9.64 (5.13,14.16) < 0.001* 19.97 (12.84,27.10) < 0.001* 
BP 5.66 (-11.46,22.78) 0.517 13.70 (9.52,17.88) < 0.001* 14.82 (7.77,21.86) < 0.001* 
GH -7.78 (-26.47,10.91) 0.415 3.54 (-0.64,7.73) 0.097 7.94 (1.23,14.64) 0.020* 
VT 6.99 (-7.83,21.80) 0.356 17.10 (13.30,20.90) < 0.001* 23.48 (14.64,32.31) < 0.001* 
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SF -6.10 (-20.61,8.40) 0.410 3.92 (-0.12,7.96) 0.057 10.73 (3.22,18.24) 0.005* 
RE 2.43 (-14.99,19.85) 0.785 6.23 (2.70,9.76) 0.001* 5.40 (0.15,10.64) 0.044* 
MH 3.31 (-9.70,16.32) 0.618 8.82 (5.78,11.86) < 0.001* 11.66 (5.67,17.65) < 0.001* 
PCS-12 -2.55 (-9.95,4.85) 0.500 3.69 (1.71,5.66) < 0.001* 6.53 (3.10,9.96) < 0.001* 
MCS-12 2.32 (-4.76,9.41) 0.520 3.64 (2.07,5.22) < 0.001* 4.43 (1.44,7.42) 0.004* 
Note: HRQOL=health-related quality of life; SD=standard deviation; FACT-P subscales: PWB=physical well-being; SWB=social well-being; 
EWB=emotional well-being; FWB=functional well-being; PCS=prostate cancer subscale; TOI=trial outcome index; SF-12v2 subscales: PF=physical 
functioning; RP=role physical; BP=bodily pain; GH=general health; VT=vitality; SF=social functioning; RE=role emotional; MH=mental health; PCS-
12=physical component summary 12; MCS-12=mental component summary 12; SES=standardized effect size; SRM=standardized response mean; 
RS=responsiveness statistic 
* Significant Difference on HRQOL between Baseline and 6-month follow-up 
† Higher scores represent a higher level of functioning or a better HRQOL. 
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Table 6. Mean Change and Area under the Receiver Operating Characteristic Curve on Discriminating  
Subjects with Worsened/Unchanged and Improved Health Status 
         
Measure/Subscale† Mean difference  (95% CI) AUC (95% CI)* Correlation (95% CI) 
Improved Vs Unchanged   
Condition-specific, FACT-P 
  PWB -1.06 (-1.70,-0.41) 0.68 (0.59,0.78) 0.25 (0.10,0.40) 
SWB -0.39 (-1.68,0.90) 0.52 (0.42,0.62) 0.05 (-0.11,0.20) 
EWB -0.94 (-1.71,-0.17) 0.62 (0.51,0.72) 0.19 (0.04,0.34) 
FWB -1.34 (-2.55,-0.12) 0.63 (0.54,0.73) 0.17 (0.02,0.32) 
PCS -2.55 (-4.01,-1.09) 0.65 (0.55,0.75) 0.27 (0.12,0.41) 
TOI -4.95 (-7.49,-2.41) 0.69 (0.60,0.79) 0.30 (0.15,0.44) 
FACT-G Total score -3.72 (-6.07,-1.38) 0.67 (0.57,0.77) 0.25 (0.09,0.39) 




PF -16.26 (-24.36,-8.16) 0.66 (0.58,0.74) 0.31 (0.16,0.44) 
RP -19.14 (-26.90,-11.37) 0.73 (0.63,0.82) 0.37 (0.22,0.50) 
BP -6.68 (-13.95,0.59) 0.60 (0.50,0.70) 0.15 (-0.01,0.30) 
GH -11.74 (-18.49,-4.99) 0.65 (0.55,0.74) 0.27 (0.12,0.41) 
VT -10.92 (-18.81,-3.03) 0.64 (0.53,0.74) 0.22 (0.06,0.36) 
SF -14.38 (-21.37,-7.38) 0.67 (0.57,0.76) 0.31 (0.16,0.45) 
RE -2.40 (-8.45,3.66) 0.51 (0.41,0.60) 0.06 (-0.10,0.22) 
MH -8.81 (-14.80,-2.82) 0.62 (0.51,0.73) 0.23 (0.07,0.37) 
PCS-12 -6.72 (-9.59,-3.86) 0.70 (0.59,0.80) 0.35 (0.21,0.48) 
MCS-12 -2.37 (-5.02,0.28) 0.57 (0.45,0.69) 0.14 (-0.02,0.29) 
Improved Vs Worsened   
Condition-specific, FACT-P 
  PWB -3.84 (-5.70,-1.99) 0.82 (0.67,0.97) 0.52 (0.28,0.70) 
SWB -1.36 (-3.43,0.72) 0.59 (0.40,0.78) 0.19 (-0.10,0.45) 
EWB -2.55 (-4.40,-0.71) 0.70 (0.55,0.86) 0.38 (0.11,0.60) 
FWB -6.15 (-8.20,-4.10) 0.89 (0.78,0.99) 0.66 (0.47,0.80) 
PCS -8.11 (-11.96,-4.25) 0.93 (0.84,1.00) 0.53 (0.29,0.71) 
TOI -18.10 (-24.71,-11.49) 0.98 (0.96,1.00) 0.63 (0.42,0.78) 
FACT-G Total score -13.91 (-19.09,-8.73) 0.89 (0.78,1.00) 0.62 (0.41,0.77) 




PF -38.97 (-57.58,-20.36) 0.82 (0.67,0.98) 0.53 (0.29,0.71) 
RP -30.25 (-44.29,-16.22) 0.82 (0.69,0.94) 0.54 (0.30,0.71) 
BP -15.76 (-30.90,-0.61) 0.64 (0.47,0.81) 0.30 (0.01,0.53) 
GH -28.82 (-43.27,-14.38) 0.79 (0.64,0.94) 0.51 (0.26,0.69) 
VT -21.01 (-37.94,-4.07) 0.71 (0.55,0.86) 0.35 (0.07,0.57) 
SF -26.79 (-40.91,-12.66) 0.81 (0.68,0.93) 0.49 (0.24,0.68) 
RE -14.29 (-26.17,-2.40) 0.64 (0.48,0.80) 0.34 (0.06,0.57) 
MH -18.07 (-30.86,-5.27) 0.73 (0.57,0.89) 0.39 (0.12,0.60) 
PCS-12 -13.31 (-19.82,-6.80) 0.80 (0.64,0.96) 0.52 (0.28,0.70) 
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MCS-12 -6.13 (-12.42,0.15) 0.64 (0.46,0.82) 0.28 (-0.01,0.52) 
Worsened Vs Unchanged   
Condition-specific, FACT-P 
  PWB -2.79 (-3.98,-1.60) 0.70 (0.52,0.88) 0.37 (0.22,0.51) 
SWB -0.97 (-2.95,1.01) 0.56 (0.40,0.73) 0.08 (-0.09,0.25) 
EWB -1.61 (-2.84,-0.38) 0.60 (0.43,0.76) 0.22 (0.05,0.38) 
FWB -4.82 (-6.68,-2.95) 0.81 (0.68,0.95) 0.41 (0.25,0.54) 
PCS -5.55 (-7.53,-3.57) 0.83 (0.72,0.94) 0.43 (0.29,0.56) 
TOI -13.15 (-17.11,-9.20) 0.89 (0.82,0.96) 0.50 (0.36,0.61) 
FACT-G Total score -10.18 (-13.89,-6.47) 0.81 (0.67,0.95) 0.43 (0.28,0.56) 




PF -22.71 (-35.69,-9.73) 0.74 (0.57,0.90) 0.29 (0.12,0.44) 
RP -11.12 (-22.75,0.51) 0.63 (0.47,0.80) 0.16 (-0.01,0.32) 
BP -9.08 (-20.46,2.31) 0.55 (0.38,0.72) 0.14 (-0.03,0.30) 
GH -17.08 (-27.54,-6.62) 0.69 (0.52,0.85) 0.27 (0.11,0.42) 
VT -10.09 (-21.29,1.11) 0.59 (0.44,0.75) 0.15 (-0.02,0.31) 
SF -12.41 (-21.81,-3.01) 0.69 (0.54,0.84) 0.22 (0.05,0.38) 
RE -11.89 (-21.52,-2.26) 0.63 (0.48,0.79) 0.21 (0.04,0.36) 
MH -9.26 (-17.71,-0.80) 0.64 (0.46,0.82) 0.19 (0.02,0.34) 
PCS-12 -6.59 (-10.74,-2.44) 0.67 (0.47,0.86) 0.26 (0.10,0.41) 




AUC=Area under the receiver operating characteristic curve; HRQOL=health-related quality of life; 
SD=standard deviation; FACT-P subscales: PWB=physical well-being; SWB=social well-being; 
EWB=emotional well-being; FWB=functional well-being; PCS=prostate cancer subscale; TOI=trial 
outcome index; SF-12v2 subscales: PF=physical functioning; RP=role physical; BP=bodily pain; 
GH=general health; VT=vitality; SF=social functioning; RE=role emotional; MH=mental health; 
PCS-12=physical component summary 12; MCS-12=mental component summary 12 
* The AUC ≥ 0.7 was considered adequate. 
† Higher scores represent a higher level of functioning or a better HRQOL. 
 
